ArticleScientific reports2026
A long-range enhancer at -52Kb drives expression of the COUP-TFII transcription factor in erythroid cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
COUP-TFII, encoded by the NR2F2 gene, is an orphan nuclear receptor highly expressed during embryonic development in several tissues. In erythropoiesis, COUP-TFII is active in yolk sac-derived cells prior to the switch to adult globin expression. Its broad expression pattern suggests a complex transcriptional regulation involving multiple, yet poorly defined, regulatory elements. Using integrative in silico and chromatin accessibility analyses, here we identified an erythroid-specific enhancer located 52Kb upstream of the NR2F2 transcription start site. This element shows epigenetic features of an active enhancer in K562 erythroid cells. Notably, in subclones derived from adult HUDEP2 erythroid progenitor cells that spontaneously re-express fetal gamma globin, NR2F2 is reactivated, concomitantly with the opening of the -52Kb enhancer. We also identify the transcription factor ZBTB7A as a repressor of NR2F2, as knock-out of ZBTB7A in HUDEP2 cells restores NR2F2 expression and active chromatin marks at the -52Kb region. Our findings uncover a novel distal enhancer controlling NR2F2 expression in erythroid cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.